Table 1.
Characteristic | Rosuvastatin Initiators | Atorvastatin Initiators | Standardized Mean Differences (%) |
---|---|---|---|
No. of cohorts | 40 | 40 | − |
No. of participants | 152,101 | 795,799 | − |
Age, mean (SD), yr | 60.6 (11.7) | 60.0 (12.2) | 5.37 |
Women, n (%) | 77,230 (50.8) | 373,794 (47.0) | 7.62 |
Race/ethnicity, n (%) | |||
Black | 12,099 (8.0) | 80,224 (10.1) | −7.17 |
Hispanic | 6006 (3.9) | 31,287 (3.9) | 0.09 |
White | 125,853 (82.7) | 641,237 (80.6) | 5.51 |
Othera | 8143 (5.4) | 43,051 (5.4) | −0.25 |
eGFR, mean (SD), ml/min per 1.73 m2 | 80.5 (18.9) | 81.7 (19.4) | −6.17 |
eGFR category, n (%) | |||
≥60 ml/min per 1.73 m2 | 130,506 (85.8) | 687,461 (86.4) | −1.70 |
30–59 ml/min per 1.73 m2 | 20,427 (13.4) | 102,392 (12.9) | 1.68 |
<30 ml/min per 1.73 m2 | 1168 (0.8) | 5946 (0.7) | 0.24 |
BMI, mean (SD), kg/m2 | 30.9 (6.5) | 31.3 (6.9) | −5.45 |
Smoking, n (%) | |||
Current | 9620 (6.3) | 63,557 (8.0) | −6.23 |
Former | 25,142 (16.5) | 137,723 (17.3) | −2.06 |
Never | 117,339 (77.1) | 594,519 (74.7) | 5.64 |
SBP, mean (SD), mm Hg | 128.1 (16.0) | 129.1 (16.5) | −6.08 |
Serum K, mean (SD), mmol/L | 4.31 (0.41) | 4.28 (0.41) | 6.92 |
Comorbidities, n (%) | |||
Diabetes | 42,904 (28.2) | 236,744 (29.7) | −3.38 |
Hypertension | 100,712 (66.2) | 535,710 (67.3) | −2.35 |
Coronary artery disease | 39,031 (25.7) | 185,365 (23.3) | 5.57 |
Cerebrovascular disease | 14,506 (9.5) | 84,096 (10.6) | −3.38 |
Heart failure | 8156 (5.4) | 51,274 (6.4) | −4.46 |
Hypothyroidism | 26,445 (17.4) | 120,861 (15.2) | 6.07 |
Concomitant medications, n (%) | |||
ACE inhibitors | 28,348 (18.6) | 182,927 (23.0) | −10.46 |
ARBs | 18,941 (12.5) | 81,497 (10.2) | 7.19 |
Aldosterone antagonists | 2022 (1.3) | 11,702 (1.5) | −1.18 |
Other HTN medications | 49,370 (32.5) | 278,790 (35.0) | −5.41 |
SGLT2 inhibitors | 1594 (1.0) | 6259 (0.8) | 2.88 |
DPP4 inhibitors | 3189 (2.1) | 13,004 (1.6) | 3.57 |
GLP1RAs | 1731 (1.1) | 6883 (0.9) | 2.88 |
Other oral DM medications | 19,859 (13.1) | 123,491 (15.5) | −6.87 |
Insulin | 6236 (4.1) | 35,886 (4.5) | −1.99 |
DOACs | 1715 (1.1) | 11,651 (1.5) | −2.85 |
Warfarin | 2481 (1.6) | 15,881 (2.0) | −2.64 |
Antiplatelets | 7879 (5.2) | 50,054 (6.3) | −4.63 |
Cyclosporine | 143 (0.1) | 474 (0.1) | 1.35 |
Itraconazole | 28 (0.0) | 152 (0.0) | −0.05 |
Clarithromycin | 105 (0.1) | 435 (0.1) | 0.60 |
Protease inhibitors | 76 (0.0) | 323 (0.0) | 0.46 |
Fibrates | 5605 (3.7) | 18,874 (2.4) | 8.28 |
Niacin | 1422 (0.9) | 3241 (0.4) | 7.54 |
PCSK9 inhibitor | 100 (0.1%) | 59 (0.0) | 4.50 |
Ezetimibe | 3850 (2.5) | 7251 (0.9) | 15.08 |
Baseline year, n (%) | |||
2011 | 12,993 (8.5) | 23,568 (3.0) | 29.15 |
2012 | 14,013 (9.2) | 47,819 (6.0) | 12.99 |
2013 | 12,756 (8.4) | 65,200 (8.2) | 0.70 |
2014 | 15,270 (10.0) | 94,762 (11.9) | −5.83 |
2015 | 14,744 (9.7) | 116,337 (14.6) | −14.29 |
2016 | 14,646 (9.6) | 120,628 (15.2) | −15.83 |
2017 | 18,307 (12.0) | 115,576 (14.5) | −7.14 |
2018 | 21,633 (14.2) | 105,943 (13.3) | 2.67 |
2019 | 27,739 (18.2) | 105,966 (13.3) | 14.16 |
Total cholesterolb | |||
Missing, n (%) | 42,028 (27.6) | 219,096 (27.5) | |
Mean (SD), mmol/L | 4.9 (1.0) | 5.0 (1.0) | −7.16 |
LDL cholesterolb | |||
Missing | 32,169 (21.1) | 164,774 (20.7) | |
Mean (SD), mmol/L | 3.5 (1.0) | 3.5 (1.0) | 2.61 |
BMI, body mass index; SBP, systolic BP; ACE inhibitors, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; SGLT2 inhibitors, sodium-glucose cotransporter 2 inhibitors; DPP4 inhibitors, dipeptidyl peptidase-4 inhibitor; GLP1RAs, glucagon-like peptide 1 receptor agonists; DOACs, direct oral anticoagulants; PCSK9 inhibitors, proprotein convertase subtilisin/kexin type 9 inhibitors.
Other includes Asian patients and patients with unknown race/ethnicity.
Only among patients with values available. Cholesterol level was not included in the propensity score model.